ClinicalTrials.gg
RecruitingNCT06663748Updated Oct 16, 2026

ARX788 in HER2-positive Metastatic Breast Cancer Patients

A Phase 2 interventional study of ARX788 in HER2-positive, Metastatic Breast Cancer, sponsored by Henan Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Henan Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 16, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing ARX788 in Breast Neoplasms — 3 open to participants now, 5 under way, 1 of them phase 3. ARX788 · Breast Neoplasms.

Planned enrollment
6th of 10
44 · median 49
Started
2025
the only one that year
Phase 2
7 of 10
3 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Henan Cancer Hospital

Among the 10 studies testing ARX788 in Breast Neoplasms, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 7 in phase 2, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 10 studies testing ARX788 in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ARX788

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ARX788 in Breast Neoplasms, or all of them as a file.
02

Study summary

A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.

Read the detailed description

A single arm, phase 2 study of ARX788 in HER2-positive, metastatic breast cancer patients. The ARX788 will be administered every 6 weeks (Q6W) intravenous (IV) infusion.

03

Conditions studied

  • HER2-positive, Metastatic Breast Cancer

Browse trials for

Keywords

  • ARX788
  • HER2-positive breast cancer
  • Q6W
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 75 years old (including upper and lower limits), male or female;
  • Unresectable locally advanced, recurrent or BC;
  • Has previously received ≤ two (excluding hormone therapy) for recurrent or metastatic BC;
  • Tissue samples determined to be positive (defined as IHC3+ or FISH+);
  • Has at least one measurable target lesion as per RECIST1.1 criteria;
  • Has recovered from any AE (≤ Grade 1) related to prior surgery and prior cancer treatment;
  • Adequate bone marrow, liver, kidney and coagulation function;
  • Performance Status Score of 0-1;
  • Voluntarily sign the , have good compliance and are willing to comply with the follow-up visit.

Exclusion criteria

Exclusion Criteria:

  • Has known history to be allergic to any active ingredient or of ARX788;
  • With meningeal or disseminated or active brain metastases, who need radiation, surgery or drug therapy;
  • Has pericardial effusion, pleural effusion or ascites effusion with clinical symptoms, signs or require symptomatic treatment;
  • Has interstitial lung disease requiring therapy, a history of drug-induced interstitial lung disease, a history of radiation pneumonitis, or any evidence indicating clinically active interstitial lung disease;
  • Has any eye disease that require medical intervention such as keratitis, corneal diseases or active eye infection;
  • Has cardiac insufficiency;
  • Uncontrolled hypertension;
  • Has evidence of severe or uncontrollable systemic diseases;
  • Received within 4 weeks before the first use of the product or plans to receive live vaccines during the trial;
  • Breastfeeding female, or who has with a positive baseline pregnancy test or who is unwilling to use effective during the trial;
  • Is unwilling or unable to stop wearing corneal contact lens during the trial;
  • Has received any systemic anti-tumor therapy (with the exception of endocrine therapy, with an interval of at least 7 days) within 28 days (or at least 5 half-lives) before the first use of the investigational product;
  • Has any mental or cognitive disorder that may restrict his/her understanding and execution of the form;
  • Other conditions that the Investigator considers inappropriate for participation in this trial, such as poor compliance.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    ARX788

    Drug: ARX788

Interventions

  • DrugARX788

    2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.

06

What researchers measure

Primary outcomes

  1. Objective remission rate (ORR)

    ORR is defined as the percentage of participants in the analysis population who have CR or PR per RECIST 1.1.

    Time frame: up to 2 years

Secondary outcomes

  1. Disease control rate (DCR)

    DCR is defined as the percentage of participants in the analysis population who have CR or PR or SD per RECIST 1.1.

    Time frame: up to 2 years

  2. Duration of relief (DOR)

    DOR is defined as the interval from response initiation (when either CR or PR is first determined) to progression or death, whichever occurs first.

    Time frame: From response initiation (when either CR or PR is first determined) to progression or death, whichever occurs first, assessed up to 2 years.

  3. Progression-free survival (PFS)

    PFS was defined as the time from first dose to first documented disease progression (PD) or death from any cause, whichever occurred first.

    Time frame: From first dose to first documented disease progression (PD) or death from any cause, whichever occurred first, assessed up to 2 years.

  4. Overall survival (OS)

    OS was defined as the time from the first dose of study drug to any-cause death.

    Time frame: From the date of first dose of study drug to any-cause death, assessed up to 5 years

  5. The number of subjects experiencing adverse event TEAEs

    Number of participants with TEAEs as assessed by CTCAE v5.0

    Time frame: up to 2 years

  6. Pharmacokinetic parameter: Maximum concentration (Cmax)

    Time frame: At the end of Cycle 1 (each cycle is 42 days)

  7. Pharmacokinetic parameter: Time to Cmax (tmax)

    Time frame: At the end of Cycle 1 (each cycle is 42 days)

  8. Pharmacokinetic parameter: Terminal half-life (t1/2)

    Time frame: At the end of Cycle 1 (each cycle is 42 days)

  9. Pharmacokinetic parameter: Area under the concentration-time curve from zero extrapolated to infinity [AUC(0-inf)]

    Time frame: At the end of Cycle 1 (each cycle is 42 days)

  10. Pharmacokinetic parameter: Area under the concentration-time curve from zero to the last quantifiable concentration [AUC(0-last)]

    Time frame: At the end of Cycle 1 (each cycle is 42 days)

  11. Pharmacokinetic parameter: Terminal rate constant (λz)

    Time frame: At the end of Cycle 1 (each cycle is 42 days)

  12. Pharmacokinetic parameter: Systemic clearance (CL)

    Time frame: At the end of Cycle 1 (each cycle is 42 days)

  13. Pharmacokinetic parameter: Volume of distribution (Vz)

    Time frame: At the end of Cycle 1 (each cycle is 42 days)

  14. Pharmacokinetic parameter: Volume of distribution at steady state (Vss)

    Time frame: At the end of Cycle 3 (each cycle is 42 days)

  15. Pharmacokinetic parameter: Trough concentration (Ctrough)

    Time frame: At the end of Cycle 3 (each cycle is 42 days)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2027, 29 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 29 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Nov 2024 → Jun 2025 and primary completion Nov 2025 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Oct 29, 2024
StartActual
Jun 16, 2025was Nov 2024
Primary completionEst.
Nov 20, 2027was Nov 2025
CompletionEst.
Nov 20, 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
1 site added — first site in China
Show site
  • Henan Cancer Hospital · Zhengzhou, China
Oct 16, 2026
Start date
Nov 20, 2024→Jun 16, 2025 (actual)
Oct 16, 2026
Primary completion
Nov 20, 2025→Nov 20, 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Henan Cancer Hospital · Zhengzhou, China
    Start date Nov 20, 2024→Jun 16, 2025 (now actual)
    Primary completion Nov 20, 2025→Nov 20, 2027
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06663748
Responsible party
Min Yan, MD (Chief Physician, Henan Cancer Hospital) — Principal investigator
First posted
Oct 29, 2024
Start date
Jun 16, 2025
Primary completion
Nov 20, 2027 (estimated)
Completion
Nov 20, 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

Min Yan
Contact
ym200678@126.com
+86 15713857388

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARX788

Start the discussion